AIMS AND BACKGROUND: The study was performed to assess the status of immunohistochemical markers in primary and metastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. METHODS: Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. RESULTS: In the analysis of 13 cases of paired primary and metastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in liver metastasis were predominant. Bone metastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions. CONCLUSIONS: Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).
AIMS AND BACKGROUND: The study was performed to assess the status of immunohistochemical markers in primary and metastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. METHODS: Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. RESULTS: In the analysis of 13 cases of paired primary and metastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in liver metastasis were predominant. Bone metastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions. CONCLUSIONS: Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).
Authors: George Somlo; Sean K Lau; Paul Frankel; H Ben Hsieh; Xiaohe Liu; Lixin Yang; Robert Krivacic; Richard H Bruce Journal: Breast Cancer Res Treat Date: 2011-04-16 Impact factor: 4.872
Authors: Eran Sadot; Ser Yee Lee; Constantinos T Sofocleous; Stephen B Solomon; Mithat Gönen; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Clifford A Hudis; Michael I D'Angelica Journal: Ann Surg Date: 2016-07 Impact factor: 12.969
Authors: C Dilara Savci-Heijink; Hans Halfwerk; Gerrit K J Hooijer; Hugo M Horlings; Jelle Wesseling; Marc J van de Vijver Journal: Breast Cancer Res Treat Date: 2015-03-29 Impact factor: 4.872